BIONOMICS LIMITED - Announcements

Currently unlisted. Add to my watchlist

Bionomics Limited (Bionomics) is an Australia-bases clinical-stage biopharmaceutical... Bionomics Limited (Bionomics) is an Australia-bases clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders. The Company operates in drug development segment in Australia. The Company is advancing its lead drug candidate, BNC210, which is an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). The Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BNO	Suspension from Official Quotation	PRICE SENSITIVE	25/08/23	87.05KB	Share
BNO	Quarterly Activities/Appendix 4C Cash Flow Report June 2023	PRICE SENSITIVE	31/07/23	332.62KB	Share
BNO	Shareholder communication on the De-listing process	PRICE SENSITIVE	28/07/23	641.02KB	Share
BNO	Bionomics announces voluntary delisting from ASX	PRICE SENSITIVE	25/07/23	139.81KB	Share
BNO	Trading Halt	PRICE SENSITIVE	24/07/23	112.28KB	Share
BNO	BNO announces establishment of At-The-Market Equity Program	PRICE SENSITIVE	08/05/23	958.13KB	Share
BNO	Quarterly Activities/Appendix 4C Cash Flow Report Mar 2023	PRICE SENSITIVE	28/04/23	323.52KB	Share
BNO	Response to ASX Aware Query	PRICE SENSITIVE	14/03/23	226.36KB	Share
BNO	Response to ASX Price Query	PRICE SENSITIVE	09/03/23	245.65KB	Share
BNO	PREVAIL Data Disclosure Presentation	PRICE SENSITIVE	09/03/23	3.64MB	Share
BNO	Pause in Trading	PRICE SENSITIVE	09/03/23	116.05KB	Share
BNO	Follow-up Analysis from PREVAIL Phase 2 Study of BNC210 in S	PRICE SENSITIVE	09/03/23	119.07KB	Share
BNO	Trading Halt	PRICE SENSITIVE	08/03/23	133.41KB	Share
BNO	Pause in Trading	PRICE SENSITIVE	08/03/23	116.26KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/23	405.77KB	Share
BNO	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/23	133.22KB	Share
BNO	BNO Reports Topline Results in PREVAIL Phase2 Study BNC210	PRICE SENSITIVE	19/12/22	108.04KB	Share
BNO	BNO appoints Dr. Spyros Papapetropoulos as President and CEO	PRICE SENSITIVE	16/12/22	111.21KB	Share
BNO	BNO Announces Closure of US$5m Offering in the US	PRICE SENSITIVE	22/11/22	216.77KB	Share
BNO	BNO Announces Pricing of Underwritten Offering of ADS	PRICE SENSITIVE	17/11/22	115.11KB	Share
BNO	Amendment of Form F-1 for Proposed Offering of ADS's in US	PRICE SENSITIVE	15/11/22	1.99MB	Share
BNO	Trading Halt	PRICE SENSITIVE	15/11/22	154.33KB	Share
BNO	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/10/22	307.65KB	Share
BNO	R&D tax incentive refund for FY2022 received	PRICE SENSITIVE	18/10/22	76.63KB	Share
BNO	Bionomics reports Full Year Financial Results 30 June 2022	PRICE SENSITIVE	25/08/22	94.66KB	Share
BNO	Appendix 4E and Full Year Financial Statements 30 June 2022	PRICE SENSITIVE	25/08/22	1.09MB	Share
BNO	R&D tax incentive refund for FY2021 received	PRICE SENSITIVE	08/08/22	48.1KB	Share
BNO	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	144.56KB	Share
BNO	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	384.38KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/22	496.92KB	Share
BNO	Quarterly Activities/Appendix 4C Cash Flow Report Dec 2021	PRICE SENSITIVE	28/01/22	246.36KB	Share
BNO	Full Exercise of Underwriter's Option to Purchase ADSs in US	PRICE SENSITIVE	06/01/22	230.68KB	Share
BNO	Bionomics Announces Pricing of IPO in the US	PRICE SENSITIVE	16/12/21	108.41KB	Share
BNO	Trading Halt	PRICE SENSITIVE	16/12/21	221.5KB	Share
BNO	Pause in Trading	PRICE SENSITIVE	16/12/21	114.01KB	Share
BNO	Bionomics Announces Launch of Proposed IPO in the US	PRICE SENSITIVE	14/12/21	186.82KB	Share
BNO	2021 AGM Executive Chairman's Presentation	PRICE SENSITIVE	02/12/21	929.59KB	Share
BNO	Fast Track Designation for BNC210 in Social Anxiety Disorder	PRICE SENSITIVE	01/12/21	194.35KB	Share
BNO	BNO Files Registration Statement for Proposed IPO in the US	PRICE SENSITIVE	23/11/21	178.1KB	Share
BNO	Update on Possible Capital Distribution	PRICE SENSITIVE	19/11/21	85.19KB	Share
BNO	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/21	245.77KB	Share
BNO	BNO prepares BNC210 for start of Phase 2 Acute SAD trial	PRICE SENSITIVE	20/09/21	186.76KB	Share
BNO	Correction to Appendix 4E	PRICE SENSITIVE	31/08/21	196.94KB	Share
BNO	Preliminary Final Report FY2021 App 4E and Announcement	PRICE SENSITIVE	25/08/21	262.97KB	Share
BNO	BNO Announces Planned Capital Distribution to Shareholders	PRICE SENSITIVE	02/08/21	187.58KB	Share
BNO	BNO Announces Plans to Conduct U.S. Initial Public Offering	PRICE SENSITIVE	02/08/21	162.74KB	Share
BNO	Quarterly Activities and Cashflow Report	PRICE SENSITIVE	29/07/21	247.97KB	Share
BNO	BNO Initiates Phase 2b ATTUNE Study of BNC210 in PTSD	PRICE SENSITIVE	06/07/21	237.02KB	Share
BNO	Bionomics Announces Early Repayment of Debt	PRICE SENSITIVE	03/05/21	167.1KB	Share
BNO	Quarterly Cashflow Report Mar 2021	PRICE SENSITIVE	23/04/21	334.57KB	Share
BNO	Results of Entitlement Offer and Concurrent Placement	PRICE SENSITIVE	06/04/21	174.33KB	Share
BNO	Concurrent Placement with Entitlement Offer to be Conducted	PRICE SENSITIVE	17/03/21	86.39KB	Share
BNO	Bionomics Ltd Entitlement Offer Booklet	PRICE SENSITIVE	08/03/21	419.83KB	Share
BNO	Bionomics Ltd Announces Non-Renounceable Entitlement Offer	PRICE SENSITIVE	08/03/21	99.68KB	Share
BNO	Completion of Placement	PRICE SENSITIVE	02/03/21	86.73KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/21	491.21KB	Share
BNO	Positive BNC210 PK Results for Solid Dose Formulation	PRICE SENSITIVE	22/02/21	194.29KB	Share
BNO	$16 Million Capital Raise to Progress BNC210 PTSD Trial	PRICE SENSITIVE	09/02/21	104.81KB	Share
BNO	Response to ASX Price Query	PRICE SENSITIVE	05/02/21	263.82KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/21	360.92KB	Share
BNO	BNO Initiates 7-Day Dosing Pharmacokinetic Study of BNC210	PRICE SENSITIVE	04/01/21	93.64KB	Share
BNO	Bionomics Licenses Drug Candidate BNC101 to Carina Biotech	PRICE SENSITIVE	19/11/20	127.88KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	23/10/20	317.36KB	Share
BNO	Bionomics Successfully Completes Retail Entitlement Offer	PRICE SENSITIVE	20/10/20	140.57KB	Share
BNO	Bionomics Receives R&D Tax Incentive Refund of $2.9M	PRICE SENSITIVE	13/10/20	83.99KB	Share
BNO	Bionomics Retail Entitlement Offer Booklet	PRICE SENSITIVE	01/10/20	1.96MB	Share
BNO	BNO Successfully Completes Institutional Entitlement Offer	PRICE SENSITIVE	28/09/20	144.76KB	Share
BNO	Investor Presentation Pro Rata Entitlement Offer	PRICE SENSITIVE	24/09/20	718.8KB	Share
BNO	BNO Announces Accelerated Non-Renounceable Entitlement Offer	PRICE SENSITIVE	24/09/20	107.17KB	Share
BNO	Trading Halt	PRICE SENSITIVE	24/09/20	136.04KB	Share
BNO	FIRB Approval Granted	PRICE SENSITIVE	23/09/20	91.8KB	Share
BNO	2019/2020 Preliminary Final Report	PRICE SENSITIVE	28/08/20	182.36KB	Share
BNO	Response to ASX Price Query	PRICE SENSITIVE	27/08/20	267.47KB	Share
BNO	Response to ASX Price Query	PRICE SENSITIVE	17/08/20	682.4KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/20	383.17KB	Share
BNO	Restatement of Accounts	PRICE SENSITIVE	21/07/20	116.95KB	Share
BNO	Recapitalisation Led by Apeiron Investment Group Ltd	PRICE SENSITIVE	02/06/20	136.13KB	Share
BNO	BNO Extends Cash Runway Through Deferral of Loan Repayments	PRICE SENSITIVE	11/05/20	90.85KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	23/04/20	362.26KB	Share
BNO	Published BNC210 Phase 2b Data, Additional Information	PRICE SENSITIVE	03/04/20	191.39KB	Share
BNO	Positive Phase 2b Data for BNC210 in GAD Patients Published	PRICE SENSITIVE	02/04/20	131.1KB	Share
BNO	Completion of Sale of Bionomics' French Subsidiaries	PRICE SENSITIVE	03/03/20	117.55KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/20	557.33KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/20	359.22KB	Share
BNO	Bionomics Corporate Presentation	PRICE SENSITIVE	29/01/20	1.03MB	Share
BNO	Sale of French Subsidiaries to Domain Therapeutics	PRICE SENSITIVE	11/12/19	118.67KB	Share
BNO	Planned Recruitment of New CEO	PRICE SENSITIVE	20/11/19	123.75KB	Share
BNO	Executive Chairman's 2019 AGM Presentation	PRICE SENSITIVE	20/11/19	1.03MB	Share
BNO	Bionomics Receives R&D Tax Incentive Refund of $5.1M	PRICE SENSITIVE	11/11/19	79.96KB	Share
BNO	FDA Grants Fast Track Designation to BNC210 PTSD Program	PRICE SENSITIVE	04/11/19	91.11KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/19	563.09KB	Share
BNO	BNC210 Solid Dose Achieves Required Blood Levels	PRICE SENSITIVE	26/09/19	91.93KB	Share
BNO	BNO - FDA Fast Track Application	PRICE SENSITIVE	19/09/19	84.66KB	Share
BNO	Bionomics 2018/2019 Preliminary Final Results	PRICE SENSITIVE	20/08/19	178.41KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	350.71KB	Share
BNO	Bionomics Receives Further R&D Tax Incentive Refund of $1.3M	PRICE SENSITIVE	22/07/19	81.14KB	Share
BNO	Presentation - BNC210 Update	PRICE SENSITIVE	26/06/19	612.31KB	Share
BNO	Results of BNC210 Agitation Trial	PRICE SENSITIVE	26/06/19	197.33KB	Share
BNO	Trading Halt	PRICE SENSITIVE	24/06/19	140.29KB	Share
BNO	Strategic Review Outcome and Program Updates	PRICE SENSITIVE	29/05/19	106.63KB	Share

BNO Suspension from Official Quotation
25/08/23	PRICE SENSITIVE	87.05KB	Share
BNO Quarterly Activities/Appendix 4C Cash Flow Report June 2023
31/07/23	PRICE SENSITIVE	332.62KB	Share
BNO Shareholder communication on the De-listing process
28/07/23	PRICE SENSITIVE	641.02KB	Share
BNO Bionomics announces voluntary delisting from ASX
25/07/23	PRICE SENSITIVE	139.81KB	Share
BNO Trading Halt
24/07/23	PRICE SENSITIVE	112.28KB	Share
BNO BNO announces establishment of At-The-Market Equity Program
08/05/23	PRICE SENSITIVE	958.13KB	Share
BNO Quarterly Activities/Appendix 4C Cash Flow Report Mar 2023
28/04/23	PRICE SENSITIVE	323.52KB	Share
BNO Response to ASX Aware Query
14/03/23	PRICE SENSITIVE	226.36KB	Share
BNO Response to ASX Price Query
09/03/23	PRICE SENSITIVE	245.65KB	Share
BNO PREVAIL Data Disclosure Presentation
09/03/23	PRICE SENSITIVE	3.64MB	Share
BNO Pause in Trading
09/03/23	PRICE SENSITIVE	116.05KB	Share
BNO Follow-up Analysis from PREVAIL Phase 2 Study of BNC210 in S
09/03/23	PRICE SENSITIVE	119.07KB	Share
BNO Trading Halt
08/03/23	PRICE SENSITIVE	133.41KB	Share
BNO Pause in Trading
08/03/23	PRICE SENSITIVE	116.26KB	Share
BNO Half Yearly Report and Accounts
23/02/23	PRICE SENSITIVE	405.77KB	Share
BNO Quarterly Activities/Appendix 4C Cash Flow Report
30/01/23	PRICE SENSITIVE	133.22KB	Share
BNO BNO Reports Topline Results in PREVAIL Phase2 Study BNC210
19/12/22	PRICE SENSITIVE	108.04KB	Share
BNO BNO appoints Dr. Spyros Papapetropoulos as President and CEO
16/12/22	PRICE SENSITIVE	111.21KB	Share
BNO BNO Announces Closure of US$5m Offering in the US
22/11/22	PRICE SENSITIVE	216.77KB	Share
BNO BNO Announces Pricing of Underwritten Offering of ADS
17/11/22	PRICE SENSITIVE	115.11KB	Share
BNO Amendment of Form F-1 for Proposed Offering of ADS's in US
15/11/22	PRICE SENSITIVE	1.99MB	Share
BNO Trading Halt
15/11/22	PRICE SENSITIVE	154.33KB	Share
BNO Quarterly Activities/Appendix 4C Cash Flow Report
25/10/22	PRICE SENSITIVE	307.65KB	Share
BNO R&D tax incentive refund for FY2022 received
18/10/22	PRICE SENSITIVE	76.63KB	Share
BNO Bionomics reports Full Year Financial Results 30 June 2022
25/08/22	PRICE SENSITIVE	94.66KB	Share
BNO Appendix 4E and Full Year Financial Statements 30 June 2022
25/08/22	PRICE SENSITIVE	1.09MB	Share
BNO R&D tax incentive refund for FY2021 received
08/08/22	PRICE SENSITIVE	48.1KB	Share
BNO Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	144.56KB	Share
BNO Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	384.38KB	Share
BNO Half Yearly Report and Accounts
23/02/22	PRICE SENSITIVE	496.92KB	Share
BNO Quarterly Activities/Appendix 4C Cash Flow Report Dec 2021
28/01/22	PRICE SENSITIVE	246.36KB	Share
BNO Full Exercise of Underwriter's Option to Purchase ADSs in US
06/01/22	PRICE SENSITIVE	230.68KB	Share
BNO Bionomics Announces Pricing of IPO in the US
16/12/21	PRICE SENSITIVE	108.41KB	Share
BNO Trading Halt
16/12/21	PRICE SENSITIVE	221.5KB	Share
BNO Pause in Trading
16/12/21	PRICE SENSITIVE	114.01KB	Share
BNO Bionomics Announces Launch of Proposed IPO in the US
14/12/21	PRICE SENSITIVE	186.82KB	Share
BNO 2021 AGM Executive Chairman's Presentation
02/12/21	PRICE SENSITIVE	929.59KB	Share
BNO Fast Track Designation for BNC210 in Social Anxiety Disorder
01/12/21	PRICE SENSITIVE	194.35KB	Share
BNO BNO Files Registration Statement for Proposed IPO in the US
23/11/21	PRICE SENSITIVE	178.1KB	Share
BNO Update on Possible Capital Distribution
19/11/21	PRICE SENSITIVE	85.19KB	Share
BNO Quarterly Activities/Appendix 4C Cash Flow Report
29/10/21	PRICE SENSITIVE	245.77KB	Share
BNO BNO prepares BNC210 for start of Phase 2 Acute SAD trial
20/09/21	PRICE SENSITIVE	186.76KB	Share
BNO Correction to Appendix 4E
31/08/21	PRICE SENSITIVE	196.94KB	Share
BNO Preliminary Final Report FY2021 App 4E and Announcement
25/08/21	PRICE SENSITIVE	262.97KB	Share
BNO BNO Announces Planned Capital Distribution to Shareholders
02/08/21	PRICE SENSITIVE	187.58KB	Share
BNO BNO Announces Plans to Conduct U.S. Initial Public Offering
02/08/21	PRICE SENSITIVE	162.74KB	Share
BNO Quarterly Activities and Cashflow Report
29/07/21	PRICE SENSITIVE	247.97KB	Share
BNO BNO Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
06/07/21	PRICE SENSITIVE	237.02KB	Share
BNO Bionomics Announces Early Repayment of Debt
03/05/21	PRICE SENSITIVE	167.1KB	Share
BNO Quarterly Cashflow Report Mar 2021
23/04/21	PRICE SENSITIVE	334.57KB	Share
BNO Results of Entitlement Offer and Concurrent Placement
06/04/21	PRICE SENSITIVE	174.33KB	Share
BNO Concurrent Placement with Entitlement Offer to be Conducted
17/03/21	PRICE SENSITIVE	86.39KB	Share
BNO Bionomics Ltd Entitlement Offer Booklet
08/03/21	PRICE SENSITIVE	419.83KB	Share
BNO Bionomics Ltd Announces Non-Renounceable Entitlement Offer
08/03/21	PRICE SENSITIVE	99.68KB	Share
BNO Completion of Placement
02/03/21	PRICE SENSITIVE	86.73KB	Share
BNO Half Yearly Report and Accounts
26/02/21	PRICE SENSITIVE	491.21KB	Share
BNO Positive BNC210 PK Results for Solid Dose Formulation
22/02/21	PRICE SENSITIVE	194.29KB	Share
BNO $16 Million Capital Raise to Progress BNC210 PTSD Trial
09/02/21	PRICE SENSITIVE	104.81KB	Share
BNO Response to ASX Price Query
05/02/21	PRICE SENSITIVE	263.82KB	Share
BNO Appendix 4C - quarterly
29/01/21	PRICE SENSITIVE	360.92KB	Share
BNO BNO Initiates 7-Day Dosing Pharmacokinetic Study of BNC210
04/01/21	PRICE SENSITIVE	93.64KB	Share
BNO Bionomics Licenses Drug Candidate BNC101 to Carina Biotech
19/11/20	PRICE SENSITIVE	127.88KB	Share
BNO Appendix 4C - quarterly
23/10/20	PRICE SENSITIVE	317.36KB	Share
BNO Bionomics Successfully Completes Retail Entitlement Offer
20/10/20	PRICE SENSITIVE	140.57KB	Share
BNO Bionomics Receives R&D Tax Incentive Refund of $2.9M
13/10/20	PRICE SENSITIVE	83.99KB	Share
BNO Bionomics Retail Entitlement Offer Booklet
01/10/20	PRICE SENSITIVE	1.96MB	Share
BNO BNO Successfully Completes Institutional Entitlement Offer
28/09/20	PRICE SENSITIVE	144.76KB	Share
BNO Investor Presentation Pro Rata Entitlement Offer
24/09/20	PRICE SENSITIVE	718.8KB	Share
BNO BNO Announces Accelerated Non-Renounceable Entitlement Offer
24/09/20	PRICE SENSITIVE	107.17KB	Share
BNO Trading Halt
24/09/20	PRICE SENSITIVE	136.04KB	Share
BNO FIRB Approval Granted
23/09/20	PRICE SENSITIVE	91.8KB	Share
BNO 2019/2020 Preliminary Final Report
28/08/20	PRICE SENSITIVE	182.36KB	Share
BNO Response to ASX Price Query
27/08/20	PRICE SENSITIVE	267.47KB	Share
BNO Response to ASX Price Query
17/08/20	PRICE SENSITIVE	682.4KB	Share
BNO Appendix 4C - quarterly
30/07/20	PRICE SENSITIVE	383.17KB	Share
BNO Restatement of Accounts
21/07/20	PRICE SENSITIVE	116.95KB	Share
BNO Recapitalisation Led by Apeiron Investment Group Ltd
02/06/20	PRICE SENSITIVE	136.13KB	Share
BNO BNO Extends Cash Runway Through Deferral of Loan Repayments
11/05/20	PRICE SENSITIVE	90.85KB	Share
BNO Appendix 4C - quarterly
23/04/20	PRICE SENSITIVE	362.26KB	Share
BNO Published BNC210 Phase 2b Data, Additional Information
03/04/20	PRICE SENSITIVE	191.39KB	Share
BNO Positive Phase 2b Data for BNC210 in GAD Patients Published
02/04/20	PRICE SENSITIVE	131.1KB	Share
BNO Completion of Sale of Bionomics' French Subsidiaries
03/03/20	PRICE SENSITIVE	117.55KB	Share
BNO Half Yearly Report and Accounts
28/02/20	PRICE SENSITIVE	557.33KB	Share
BNO Appendix 4C - quarterly
30/01/20	PRICE SENSITIVE	359.22KB	Share
BNO Bionomics Corporate Presentation
29/01/20	PRICE SENSITIVE	1.03MB	Share
BNO Sale of French Subsidiaries to Domain Therapeutics
11/12/19	PRICE SENSITIVE	118.67KB	Share
BNO Planned Recruitment of New CEO
20/11/19	PRICE SENSITIVE	123.75KB	Share
BNO Executive Chairman's 2019 AGM Presentation
20/11/19	PRICE SENSITIVE	1.03MB	Share
BNO Bionomics Receives R&D Tax Incentive Refund of $5.1M
11/11/19	PRICE SENSITIVE	79.96KB	Share
BNO FDA Grants Fast Track Designation to BNC210 PTSD Program
04/11/19	PRICE SENSITIVE	91.11KB	Share
BNO Appendix 4C - quarterly
28/10/19	PRICE SENSITIVE	563.09KB	Share
BNO BNC210 Solid Dose Achieves Required Blood Levels
26/09/19	PRICE SENSITIVE	91.93KB	Share
BNO BNO - FDA Fast Track Application
19/09/19	PRICE SENSITIVE	84.66KB	Share
BNO Bionomics 2018/2019 Preliminary Final Results
20/08/19	PRICE SENSITIVE	178.41KB	Share
BNO Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	350.71KB	Share
BNO Bionomics Receives Further R&D Tax Incentive Refund of $1.3M
22/07/19	PRICE SENSITIVE	81.14KB	Share
BNO Presentation - BNC210 Update
26/06/19	PRICE SENSITIVE	612.31KB	Share
BNO Results of BNC210 Agitation Trial
26/06/19	PRICE SENSITIVE	197.33KB	Share
BNO Trading Halt
24/06/19	PRICE SENSITIVE	140.29KB	Share
BNO Strategic Review Outcome and Program Updates
29/05/19	PRICE SENSITIVE	106.63KB	Share

REFRESH

1 2 3

BIONOMICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available